Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more
Appili Therapeutics Inc (APLIF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.049x
Based on the latest financial reports, Appili Therapeutics Inc (APLIF) has a cash flow conversion efficiency ratio of 0.049x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-759.38K) by net assets ($-15.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Appili Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Appili Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Appili Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Appili Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TAQA MOROCCO
BC:TAQA-MOROCCO
|
N/A |
|
Valhalla Metals Inc.
OTCQB:VMXXF
|
-0.297x |
|
Welltower OP LLC
STU:HCW
|
0.020x |
|
EITZEN CHEMICALS
F:E8H
|
-0.006x |
|
Reflect Scientific Inc
OTCQB:RSCF
|
-0.035x |
|
Revelation Biosciences Inc
NASDAQ:REVB
|
-0.144x |
|
AMETEK
BE:AK1
|
0.051x |
|
Franklin Mining Inc
PINK:FMNJ
|
0.368x |
Annual Cash Flow Conversion Efficiency for Appili Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Appili Therapeutics Inc from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $-13.40 Million | $868.82K | -0.065x | -128.75% |
| 2024-03-31 | $-10.92 Million | $-2.46 Million | 0.226x | -96.13% |
| 2023-03-31 | $-3.27 Million | $-19.08 Million | 5.834x | +749.77% |
| 2022-03-31 | $12.75 Million | $-11.45 Million | -0.898x | -86.42% |
| 2021-03-31 | $8.85 Million | $-4.26 Million | -0.482x | +38.42% |
| 2020-03-31 | $4.42 Million | $-3.46 Million | -0.782x | 0.00% |
| 2019-03-31 | $4.42 Million | $-3.46 Million | -0.782x | -15.22% |
| 2018-03-31 | $4.87 Million | $-3.30 Million | -0.679x | +56.34% |
| 2017-03-31 | $1.37 Million | $-2.14 Million | -1.555x | -- |